Kenvue Inc.
Kenvue Reports Q2 2025 Results and Revises Outlook
Summary
Kenvue Inc. reported financial results for the second quarter of 2025, showing a net sales decrease of 4.0% and organic sales decline of 4.2%, impacted by volume decline and strategic price investments. Diluted EPS was $0.22, up from $0.03 in the prior year period. The company also revised its outlook for FY 2025, anticipating low-single-digit net sales and organic sales decline, and adjusted operating income margin decline. Additionally, Kenvue appointed Kirk Perry as Interim CEO and announced leadership changes, while continuing its strategic review.
Profitelligence Alerts
Get alerts for KVUE
Be first to know when Kenvue Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Kenvue Inc.
Kenvue Inc. is a consumer healthcare and pharmaceutical company. It focuses on delivering a range of health-centric products, spanning hygiene, pain relief, and other wellness categories. With deep-rooted expertise in pharmaceuticals, Kenvue Inc. targets the health and wellness needs of individuals, providing both prescription and over-the-counter solutions. The company has established itself as a vital entity in the consumer health sector, significantly impacting community health standards and individual lives. Positioned in the pharmaceutical industry, Kenvue Inc. collaborates with healthcare providers to enhance its product reach and efficacy. Its broad portfolio includes well-known brands and formulations that are trusted globally by consumers seeking reliable health solutions. As a player in this sector, Kenvue Inc. contributes to the enhancement of public health, highlighting its prominence in both domestic and international markets.
Official SEC Documents
Advertisement